Axt Carla Wiebke, Springer Andrea, von Luckner Jennifer, Naucke Torsten J, Müller Elisabeth, Strube Christina, Schäfer Ingo
Laboklin GmbH and Co. KG, Bad Kissingen.
Institut für Parasitologie, Zentrum für Infektionsmedizin, Stiftung Tierärztliche Hochschule Hannover.
Tierarztl Prax Ausg G Grosstiere Nutztiere. 2025 Feb;53(1):49-58. doi: 10.1055/a-2457-5516. Epub 2024 Dec 4.
Equine piroplasmosis (EP) is caused by (.) and (.) and is transmitted by hard ticks. Predominantly, the Mediterranean region is known as being endemic for both pathogens in Europe. However, autochthonous infections in central European countries such as Germany can no longer be ruled out due to individual case reports in horses without any stays abroad as well as the geographical expansion of the habitats of different tick species. The case reports presented underline the risk of infection for horses travelling to endemic areas and in horses imported from such areas to non-endemic countries. Clinical signs are often unspecific and include fever, icterus, lethargy, inappetence, weight loss, and reduced performance. Mild to severe anemia is the most common hematologic abnormality, but thrombocytopenia has also been described. Direct (polymerase chain reaction, microscopical analysis of blood smears) and indirect detection methods (detection of antibodies) are available for the diagnosis of pathogen contact and/or infection. Imidocarb-dipropionate is recommended as treatment of choice against EP. Infections with can be cleared, while infections with often result in a life-long carrier status despite treatment. Prevention is limited to controlling or avoiding tick contact. Aside from potentially severe and life-threatening clinical signs, equine piroplasmosis has a significant economic impact on the international trade of horses worldwide. EP is classified as a notifiable disease according to WOAH guidelines, which recommend serological screening for and according to the respective national guidelines when travelling across borders. To date, EP is not classified as a notifiable nor reportable disease in Germany.
马焦虫病(EP)由(.)和(.)引起,通过硬蜱传播。在欧洲,地中海地区主要被认为是这两种病原体的地方病流行区。然而,由于在没有任何国外停留史的马匹中出现个别病例报告,以及不同蜱种栖息地的地理扩张,在德国等中欧国家不再能排除本土感染的可能性。所呈现的病例报告突显了前往地方病流行区的马匹以及从这些地区进口到非地方病国家的马匹的感染风险。临床症状通常不具特异性,包括发热、黄疸、嗜睡、食欲不振、体重减轻和性能下降。轻度至重度贫血是最常见的血液学异常,但也有血小板减少的描述。有直接(聚合酶链反应、血液涂片显微镜分析)和间接检测方法(抗体检测)可用于诊断病原体接触和/或感染。双丙酸咪唑苯脲被推荐为治疗马焦虫病的首选药物。感染(.)可以清除,而感染(.)尽管进行了治疗,通常仍会导致终身带菌状态。预防措施仅限于控制或避免蜱虫接触。除了可能出现严重且危及生命的临床症状外,马焦虫病对全球马匹国际贸易具有重大经济影响。根据世界动物卫生组织(WOAH)的指导方针,马焦虫病被列为应通报的疾病,该指导方针建议在跨境旅行时根据各自国家的指导方针进行(.)和(.)的血清学筛查。迄今为止,在德国,马焦虫病既未被列为应通报的疾病,也未被列为应报告的疾病。